新型脚手架解锁了强大的跨酶和跨物种抑制剂,作为有希望的抗疟疾药物
Mahta Mansouri1, Amanda De Paoli2, Carlo Giannangelo2
1Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Journal of medicinal chemistry
|January 12, 2026
概括
针对Plasmodium falciparum M1和M17氨基酶的新型双重抑制剂对疟疾治疗有希望. 这些化合物对抗耐药菌株具有广泛的活性,并在体内表现出有效性.
科学领域:
- 药用化学 医学化学
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
背景情况:
- 疟疾是一个重要的全球卫生问题,药物耐药性日益增加.
- 向Plasmodium falciparum M1和M17氨基化酶 (PfA-M1和PfA-M17) 是一种经过验证的抗疟疾药物开发策略.
研究的目的:
- 通过综合设计策略识别PfA-M1和PfA-M17的新型双重抑制剂.
- 评估这些抑制剂对各种类型的杆菌和耐药菌株的疗效.
主要方法:
- 采用基于连接体和基于结构的药物设计方法.
- 进行结构研究以了解酶-抑制剂相互作用.
- 测试了抗生素Plasmodium vivax,抗生素Plasmodium berghei和抗多药性抗生素Plasmodium falciparum菌株的抑制剂.
- 在感染Plasmodium berghei的小鼠身上进行了体内疗效研究.
主要成果:
- 确定了作为PfA-M1和PfA-M17双重抑制剂的新型支架.
- 结构分析显示了酶的S1口袋内的有利相互作用.
- 抑制剂对P.vivax,P.berghei和耐药的P.falciparum菌株具有很高的疗效,显示出跨物种活性.
- 在小鼠模型中实现了对寄生虫病的显著减少.
结论:
- 开发的双重抑制剂代表了疟疾治疗的有希望的类似药物的候选者.
- 这些化合物提供了对抗耐药疟疾寄生虫的潜在新作用机制.
- 进一步的体内研究有必要将这些候选物推向临床应用.
相关概念视频
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...